US Bancorp
KYMR icon

US Bancorp’s Kymera Therapeutics KYMR Stock Holding History

US Bancorp’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Sell
2,264
-39
-2% -$3.35K ﹤0.01% 1963
2026
Q1 		$192K Buy
2,303
+63
+3% +$4.99K ﹤0.01% 2046
2025
Q4 		$174K Buy
2,240
+375
+20% +$25.3K ﹤0.01% 2104
2025
Q3 		$106K Buy
1,865
+166
+10% +$7.49K ﹤0.01% 2325
2025
Q2 		$74.1K Buy
1,699
+575
+51% +$19.8K ﹤0.01% 2588
2025
Q1 		$30.8K Sell
1,124
-54
-5% -$1.97K ﹤0.01% 2980
2024
Q4 		$47.4K Sell
1,178
-287
-20% -$13K ﹤0.01% 2765
2024
Q3 		$69.3K Sell
1,465
-651
-31% -$28.7K ﹤0.01% 2574
2024
Q2 		$63.2K Sell
2,116
-949
-31% -$32.9K ﹤0.01% 2545
2024
Q1 		$123K Buy
3,065
+72
+2% +$2.58K ﹤0.01% 2249
2023
Q4 		$76.2K Buy
2,993
+2,698
+915% +$48.2K ﹤0.01% 2457
2023
Q3 		$4.1K Sell
295
-23
-7% -$462 ﹤0.01% 3493
2023
Q2 		$7.31K Buy
318
+23
+8% +$659 ﹤0.01% 3370
2023
Q1 		$8.74K Hold
295
– – ﹤0.01% 3333
2022
Q4 		$7.36K Buy
+295
New +$7.87K ﹤0.01% 3389
2022
Q2 		– Sell
-204
Closed -$9K – 4147
2022
Q1 		$9K Buy
+204
New +$8.62K ﹤0.01% 3412

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

US Bancorp's KYMR Position: Q2 2026 in Review

US Bancorp reduced its Kymera Therapeutics (KYMR) stake by 1.7% in Q2 2026, selling an estimated $3.35K and leaving 2,264 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #1963.

US Bancorp first reported a position in KYMR in Q1 2022 and has held it in 16 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • US Bancorp held 2,264 shares of Kymera Therapeutics worth $260K as of Q2 2026.
  • US Bancorp sold 39 Kymera Therapeutics shares in Q2 2026, an estimated $3.35K.
  • Kymera Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1963 holding.
  • US Bancorp first reported a position in Kymera Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.